友芝友生物(02496.HK)生物类似药Y225临床试验申请获批

阿斯达克财经
Dec 28, 2025

友芝友生物-B(02496.HK) 公布,生物类似药Y225的临床试验申请获中国国国家药品监督管理局批准。Y225是一种用于治疗A型血友病的双特异性抗体舒友立乐(艾美赛珠单抗注射液,抗FIX和FX)生物类似药。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10